Innovators at the Table: Hamamatsu's Path from Photons to Pathology

What does a 73-year-old Japanese photonics company have to do with your biopsy results? More than you'd think.

In this episode of PathPulse, part of our Behind the Summit series spotlighting the sponsors of the Digital Diagnostic Summit, host Bianca Collings sits down with Stephanie Fullerton, PhD, Director of Life Science Marketing, and Scott M. Blakely, Business Development Manager, at Hamamatsu Photonics. Hamamatsu's sensors have helped confirm the existence of the Higgs boson, work that earned a Nobel Prize in Physics. That same mastery of light is what's driving their work in digital pathology, where Hamamatsu has quietly been a pioneer since introducing telepathology in Japan in the mid-1990s.

Stephanie and Scott talk about what "Photon Is Our Business" actually means inside the company, how digitizing a slide changes the entire diagnostic journey for a patient, and what's kept them at Hamamatsu for a combined four decades. If you've ever wondered how a company known for physics ended up shaping how pathologists diagnose cancer, this one's for you.

Want to meet Hamamatsu and the other trailblazers behind digital pathology in person? Join us at the Digital Diagnostic Summit, August 26–28, 2026, at The St. Regis Deer Valley in Park City, Utah. Three days of sessions, hands-on conversation, and mountain-air networking with the people mapping diagnostic innovation to patient impact. [Register now →]

Watch on Youtube

Submit questions for our future recordings here: https://lumeadigital.com/ask-a-pathologist-podcast/

Sponsored by the Digital Diagnostic Summit and Lumea.